Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. (2021)
Attributed to:
The Future Vaccine Manufacturing Research Hub (Vax-Hub)
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(20)32466-1
PubMed Identifier: 33220855
Publication URI: http://europepmc.org/abstract/MED/33220855
Type: Journal Article/Review
Volume: 396
Parent Publication: Lancet (London, England)
Issue: 10267
ISSN: 0140-6736